BioCryst Pharmaceuticals (BCRX) Osake Kurssi

The business model of BioCryst Pharmaceuticals Inc. revolves around the development and commercialization of innovative oral and intravenous (IV) drugs to treat rare and serious diseases. BioCryst focuses on researching and designing small molecule drugs that target specific enzymes involved in various disease pathways. The company aims to bring novel therapies to patients with unmet medical needs by leveraging its expertise in structure-based drug design and drug development. With a focus on rare and orphan diseases, BioCryst is dedicated to improving patients' lives through the discovery and advancement of effective treatments.

BioCryst Pharmaceuticals Inc is primarily active in the biotechnology and pharmaceutical industries.

BioCryst Pharmaceuticals Inc is a renowned American biotechnology company. Founded in 1986, the company focuses on designing and developing novel small molecule drugs to treat rare diseases. With its headquarters in Durham, North Carolina, BioCryst Pharmaceuticals has established a strong presence in the pharmaceutical industry. Over the years, BioCryst Pharmaceuticals has made significant strides in advancing innovative therapies, particularly targeting areas like oncology and immunology. The company's commitment to scientific innovation and dedication to improving patient lives has earned it a reputable position in the healthcare sector. With an experienced team and a robust pipeline, BioCryst Pharmaceuticals continues to drive advancements in the field of biotechnology.

As of now, BioCryst Pharmaceuticals Inc has achieved several significant milestones. Some of these include the successful development and FDA approval of their first-in-class oral therapy, Orladeyo, for the prevention of hereditary angioedema attacks. Additionally, the company has made impressive advancements in the field of antiviral therapeutics, with the creation of galidesivir, a potential treatment for Marburg virus disease and yellow fever. Furthermore, BioCryst Pharmaceuticals Inc has consistently shown dedication to innovation and research in their pursuit of novel therapies, making them a prominent player in the pharmaceutical industry.

BioCryst Pharmaceuticals Inc primarily operates in the United States. The company is based in Durham, North Carolina, and focuses on the development and commercialization of small-molecule drugs. With a strong presence in the US, BioCryst Pharmaceuticals Inc is dedicated to advancing innovative treatments for rare and serious diseases.

BioCryst Pharmaceuticals Inc represents values of innovation, commitment, and patient-centric approach in the pharmaceutical industry. With a strong corporate philosophy centered around developing novel therapies, BioCryst strives to improve the lives of patients worldwide. The company's dedication to scientific advancement and breakthrough research is reflected in their diverse pipeline of potential treatments for rare diseases and unmet medical needs. BioCryst Pharmaceuticals Inc prioritizes collaboration, ethics, and quality in its operations, exemplifying its mission to revolutionize healthcare through cutting-edge science and compassionate care.

Analyytikot asettavat tällä hetkellä BioCryst Pharmaceuticals-osakkeelle keskimääräisen tavoitehinnan 20,00 USD (mediaani: 17,00 USD), mikä merkitsee +136,1 % viimeisimpään hintaan verrattuna. Konsensus perustuu 17 analyytikkoarvioon.

BioCryst Pharmaceuticals Analyytikkojen kursstavoitteet 2026

17 analyytikkoa arvioi tällä hetkellä BioCryst Pharmaceuticals-osaketta: 14 suosittaa ostoa, 3 pitoa ja 0 myyntiä. Vuodelle 2026 analyytikot odottavat BioCryst Pharmaceuticals-yhtiöltä 710,08 M USD liikevaihtoa ja −2,16 USD osakekohtaista tulosta.

BioCryst Pharmaceuticals Analyytikkojen kursstavoitteet 2026

Nykyisellä valuuttakurssilla BioCryst Pharmaceuticals-osake noteerataan hintaan 7,59 EUR (8,47 USD).

BioCryst Pharmaceuticals-osake (BCRX) on listattuna 5 pörssissä, muun muassa: NASDAQ (BCRX), SIX (Zürich) (BO1.SW), Frankfurt (BO1.F), München (BO1.MU), Düsseldorf (BO1.DU).

BioCryst Pharmaceuticals, Inc. is a leading company in the field of biopharmaceutical research and development. The company specializes in the discovery and development of innovative therapeutics and drugs for the treatment of rare diseases and serious illnesses. BioCryst Pharmaceuticals is divided into different divisions that specialize in specific therapeutics and disease areas. One important division is the research and development of drugs for the treatment of rare genetic metabolic diseases such as adenine phosphoribosyltransferase deficiency (APRT deficiency). The prevalence of this rare disease is approximately 1 in 140,000 in the USA and Europe. Another important division of BioCryst is the development of drugs for the treatment of inflammatory diseases such as oral mucositis, which occurs as an unwanted effect during chemotherapy. BioCryst has successfully completed a phase 2 study and is currently working on the development of a drug that aims to alleviate pain and inflammatory symptoms in patients. The company is also a leader in the development of drugs for the treatment of viral diseases. It has developed an antiviral drug called Rapivab, which is used for the treatment of influenza. It was approved by the FDA in 2014 and is distributed worldwide in more than 40 countries. BioCryst Pharmaceuticals is a company focused on the discovery and development of therapeutic molecules and drugs. The company's core competencies include structural biology, crystallography, drug development, and clinical trials. The business model of BioCryst Pharmaceuticals is based on a portfolio of medical innovations that aim to meet the need for therapeutics and drugs in various medical areas. The company works closely with regulatory authorities and medical organizations to bring drugs to the market that are based on the latest scientific knowledge and meet the therapeutic needs of patients. The company also has strong partnerships with leading global pharmaceutical and biopharmaceutical companies to market its therapeutics and drugs worldwide. BioCryst Pharmaceuticals has licensed partnerships with multinational corporations such as Shionogi, Seqirus, Mundipharma, and Roche. Overall, BioCryst Pharmaceuticals is a company that conducts cutting-edge medical research and specializes in the development of effective therapeutics and drugs. Its business model is based on a constant pursuit of innovation and close partnerships with regulatory authorities and medical organizations.

odotettu liikevaihto BioCryst Pharmaceuticals on 710,08 M USD. Tämä luku perustuu nykyisiin talousarvoihin ja heijastaa yhtiön liiketoimintasuoritusta.

odotettu voitto BioCryst Pharmaceuticals on −473,72 M USD. Nettovoitto kuvastaa yhtiön kannattavuutta kaikkien kulujen vähentämisen jälkeen.

BioCryst Pharmaceuticals:n hinta-voitto-suhde (P/E) on tällä hetkellä −3,92. P/E-suhde vertaa nykyistä osakekurssia osakekohtaiseen tulokseen ja auttaa sijoittajia arvioimaan BioCryst Pharmaceuticals-osakkeen arvostusta.

BioCryst Pharmaceuticals:n hinta-myynti-suhde (P/S) on tällä hetkellä 2,62. P/S-suhde vertaa markkina-arvoa vuosittaisiin tuloihin ja toimii BioCryst Pharmaceuticals-osakkeen arvostuskennuslukuna.

BioCryst Pharmaceuticals:n Eulpool-laatuscore on 6/10.

BioCryst Pharmaceuticals:n ISIN on US09058V1035. ISIN (International Securities Identification Number) on maailmanlaajuisesti ainutlaatuinen arvopaperin tunnus.

BioCryst Pharmaceuticals:n WKN on 896047. WKN (Wertpapierkennnummer) on kuusinumeroinen saksalainen arvopaperin tunnus.

BioCryst Pharmaceuticals:n ticker on BCRX. Tämä pörssinoteeraus käytetään BioCryst Pharmaceuticals-osakkeiden kauppaan pörssissä.